112.86 +0.20 (0.18%)
After hours: 5:01PM EST
|Bid||112.51 x 900|
|Ask||112.90 x 1100|
|Day's Range||111.95 - 115.00|
|52 Week Range||82.77 - 122.15|
|Beta (5Y Monthly)||0.57|
|PE Ratio (TTM)||32.00|
|Earnings Date||Feb 17, 2020|
|Forward Dividend & Yield||2.16 (1.84%)|
|Ex-Dividend Date||Dec 25, 2019|
|1y Target Est||126.43|
Shares of Medtronic stock grappled to stay in a buy zone Tuesday after the medical technology company issued a "noisy" fiscal third-quarter earnings report, according to one analyst.
Cigna is one of a handful of private payers now covering the local company's product, which measures glucose levels for diabetes patients.
Medtronic on Tuesday warned that the fourth quarter could be hurt by a slowdown caused by the COVID-19 virus that has sickened tens of thousands in China and elsewhere.
Shares of Medtronic PLC fell 1.4% in premarket trading Tuesday, after the Dublin-based medical technology company reported a fiscal third-quarter profit that beat expectations but revenue that missed. Net income rose to $1.92 billion, or $1.42 a share, from $1.27 billion, or 94 cents a share, in the year-ago period. Excluding non-recurring items, adjusted earnings per share came to $1.44, above the FactSet consensus of $1.38. Sales grew 2.3% to $7.72 billion, below the FactSet consensus of $7.81 billion, as the company's cardiac and vascular and minimally invasive therapies segments missed expectations, the restorative therapies sales were in line and the diabetes segment sales topped expectations. The company raised its full-year EPS guidance range to $5.63 to $5.65 from $5.57 to $5.63. The stock has gained 5.5% over the past three months through Friday, while the SPDR Health Care Select Sector ETF has tacked on 7.0% and the S&P 500 has advanced 8.3%.
Revenue of $7.7 Billion Increased 2.3% Reported and 2.6% Organic GAAP Diluted EPS of $1.42 Increased 51%; Non-GAAP Diluted EPS of $1.44 Increased 12% Cash Flow from Operations.
Investing.com - Medtronic reported on Tuesday third quarter earnings that beat analysts' forecasts and revenue that fell short of expectations.
Futures: Walmart, Medtronic and InMode earnings are due Tuesday. IPO stocks InMode, Progyny, Ping are near buy points. So is Taiwan Semiconductor. Buffett-boosted RH is likely to break out.
Medtronic (MDT) to integrate Digital Surgery's business within its Surgical Robotics arm, in turn augmenting the company's position in the field of surgical AI.
Editor's note: This story has been updated to reflect the FDA's approval Friday of Agile Therapeutics' hormonal contraceptive patch Twirla. Biotech stocks were quiet in the week ending Feb. 14 amid some ...
While the moderate 2020 Democrats finished behind Bernie Sanders in New Hampshire, presidential hopefuls Amy Klobuchar, Pete Buttigieg and Joe Biden are winning over S&P 500 CEOs, as the execs vote for them with their wallets.
London-based Digital Surgery has 130 employees and makes an AI technology that identifies steps in a surgery and which tools are needed for that surgery.
Shares of Medtronic PLC were up 0.36% in trading on Thursday. The Food and Drug Administration said Wednesday that Medtronic had issued a recall of its MiniMed 600 Series Insulin Pumps after reports of 2,175 injuries and one death. The regulator said it is the most serious type of recall. A missing piece can cause incorrect dosing, which can lead to hypoglycemia or hyperglycemia in the Type 1 diabetes patients who use the device. Medtronic first notified affected patients of the recall in November. Medtronic's stock has gained 29% over the past year, while the S&P 500 is up 23%.
Medtronic's "artificial pancreas" is the subject of a recall notice after it was discovered that a part of the device can be damaged, causing the device to malfunction. The FDA declared the recall of Medtronic's MiniMed 600 series insulin pumps a Class I recall on Wednesday, its most serious classification. Medtronic is aware of 2,175 possible injuries due to device malfunction, as well as one possible death.
DUBLIN, Feb. 13, 2020 (GLOBE NEWSWIRE) -- Medtronic plc (MDT), the global leader in medical technology, today announced the acquisition of Digital Surgery, a privately-held pioneer in surgical artificial intelligence (AI), data and analytics, and digital education and training. The acquisition of Digital Surgery will strengthen the Medtronic robotic assisted surgery platform and has applicability for the Medtronic broader portfolio. “Capabilities and solutions in the data and analytics space play a critical role in our continued focus on advancing minimally invasive surgery – from education and training, to clinical decision support, to reducing cost and unwarranted variability,” said Megan Rosengarten, vice president and general manager of the Surgical Robotics business, which is part of the Minimally Invasive Therapies Group at Medtronic.
Medtronic (MDT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
In the fiscal third quarter, Medtronic (MDT) is expected to have registered strong growth for TAVR across the United States, courtesy of its higher adoption by the low-risk patient population.
DUBLIN, Feb. 10, 2020 (GLOBE NEWSWIRE) -- Medtronic plc (MDT), the global leader in medical technology, today announced it and the Medtronic Foundation are committing approximately $1.2M to coronavirus relief efforts across the globe.
The Board of Regents of the University System of Georgia on Feb. 11 approved the naming of one of the towers being constructed as part of Phase III of Tech Square in honor of William W. "Bill" George and his wife Penny George.
Few funds in IBD's ETF Leaders screen are in buy areas, but iShares U.S. Medical Devices is one of the exceptions, and it's been a good investment in the long run as well.